ClinicalTrials.gg

Program

VNZ/TEZ/D-IVA

Its studies are mostly in Cystic Fibrosis, led by Vertex Pharmaceuticals.

Furthest: phase 3, since Apr 24, 20234 company-led studies, 1 open or runningNext primary completion: Jul 30, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals41 open or runningphase 3since Apr 24, 2023Apr 24, 2023Jul 30, 2029phase 3 · NCT05844449

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2023First study: phase 3 study in Cystic FibrosisFirst studyNCT05844449 · 174 planned · United States, Australia, Canada and more
  2. Feb 29, 20242 phase 1 studies in Cystic FibrosisNCT06299709, NCT06299696
  3. Jan 8, 2026Phase 1 study in Cystic FibrosisNCT07349394 · 18 enrolled · United States

Ahead

  1. Jul 30, 2029Primary completion: phase 3 study in Cystic FibrosisNCT05844449

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07349394Cystic Fibrosis · United States1CompletedFeb 28, 202618
NCT06299709Cystic Fibrosis · United States1CompletedMay 23, 202434
NCT06299696Cystic Fibrosis · United States1CompletedApr 16, 202410
NCT05844449Cystic Fibrosis · United States, Australia, Canada and more3By invitationJul 30, 2029174

How it is read

Names in the registry

  • “VNZ/TEZ/D-IVA”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.